Goldfinch is singularly focused on discovering and developing precision therapies for patients with kidney disease. Chronic kidney disease (CKD) is a growing, global health epidemic that places an enormous social and economic burden on patients, their families, and society. CKD is a driver of mortality across age, race, and stage of disease progression, affecting over 1 in 9 people worldwide. The impact of CKD is amplified by the fact that It is not one disease, but encompasses several diseases, each with distinct causes.
